ArticleCancer science2020
Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS
Open access · goldAbstract read
In one paragraph
Article in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Prognostic implications of tumour number in intrahepatic cholangiocarcinoma.JHEP reports : innovation in hepatology · 2026Article
- Article
- Causal role of immune cells in primary liver cancer: a mendelian randomization study.BMC cancer · 2025Article
- Article
- The value of periportal hyperintensity sign from gadobenate dimeglumine-enhanced hepatobiliary phase MRI for predicting clinical outcomes in patients with decompensated cirrhosis.Insights into imaging · 2024Article
- Development and Validation of Nomograms to Predict the Overall Survival and Progression-Free Survival in Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma.Cancer management and research · 2024Article
- Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version).Journal of clinical and translational hepatology · 2023Article
- A novel mitochondria-related gene signature in esophageal carcinoma: prognostic, immune, and therapeutic features.Functional & integrative genomics · 2023Article
- Development and validation of an XGBoost model to predict 5-year survival in elderly patients with intrahepatic cholangiocarcinoma after surgery: a SEER-based study.Journal of gastrointestinal oncology · 2022Article
- Prognostic Significance of NLR, PLR, LMR and Tumor Infiltrating T Lymphocytes in Patients Undergoing Surgical Resection for Hilar Cholangiocarcinoma.Frontiers in oncology · 2022Article
- Total Cerebral Small Vessel Disease Score and Cerebral Bleeding Risk in Patients With Acute Stroke Treated With Intravenous Thrombolysis.Frontiers in aging neuroscience · 2022Article
- Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort.Journal of oncology · 2022Article
- Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.Annals of surgical oncology · 2021Article
- Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.Advances in cancer research · 2021Review
- Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma.OncoTargets and therapy · 2021Article
- Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: ISCancer science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 2 countries.
Mengxin TianKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-5315-1780
Weiren LiuKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Chenyang TaoKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zheng TangKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yufu ZhouKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Shushu SongKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-6261-8664
Lei JinKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Han WangKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xifei JiangKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Peiyun ZhouKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan FangKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Weifeng QuKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenbin DingKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuanfei PengKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiutao FuKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Shuangjian QiuKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jian ZhouKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Jia FanKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Yinghong ShiKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-1833-8988
Fudan University · CN
Funding
Selectively targeting delta opioid receptor subtypes to control drinking behaviorR01AA020401 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WHISTLER, JENNIFER L · 2011 to 2015
$1.8MChina Postdoctoral Science Foundation 2018M640343 and 2019T120305National High Technology Research and Development Program (863 Program) of China 2015AA020401National Natural Science Foundation of China 81472674National Natural Science Foundation of China 81502486National Natural Science Foundation of China 81530077National Natural Science Foundation of China 81773067National Natural Science Foundation of China 81800790National Natural Science Foundation of China 81902963NIAAA NIH HHS R01 AA020401Shanghai Committee of Science and Technology, China 16JC1404000Shanghai Education Development FoundationShanghai Municipal Education CommissionShanghai Municipal Science and Technology Major ProjectShanghai Sailing Program 19YF1407800 and 19YF1404300
Abstract
Intrahepatic cholangiocarcinoma (ICC) remains a highly heterogeneous disease with poor prognosis. Tumor-infiltrating lymphocytes were predictive in various cancers, but their prognostic value in ICC is less clear. A total of 168 ICC patients who had received liver resection were enrolled and assigned to the derivation cohort. Sixteen immune markers in tumor and peritumor regions were examined by immunohistochemistry. A least absolute shrinkage and selection operator model was used to identify prognostic markers and to establish an immune signature for ICC (IS
Indexed as
PrognosisAgedCholangiocarcinomaCohort StudiesDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHepatectomyHumansLiver NeoplasmsLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasm ProteinsNeoplasm Proteinsimmune-infiltrating cellsintrahepatic cholangiocarcinomaliver cancerprognosissurvival prediction
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.